Contineum Therapeutics Rises 13.71% as Biotech Rally Boosts Investor Confidence
Contineum Therapeutics surges 13.7% as Phase II data, new partnerships and a lean balance sheet spark investor confidence, positioning the biotech stock for sustained growth.
- CONTINEUM THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read